10-Q quarterly report · filed Nov 16, 2026

MapLight Therapeutics, Inc. (MPLT) Q3 2026 10-Q Quarterly Report

Short answer

MapLight Therapeutics, Inc. (MPLT) filed its Q3 2026 10-Q quarterly report on Nov 16, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
−$52M
+36.7% YoY · +14.2% QoQ
EPS (diluted)
−$0.94
+99.1% YoY · +28.8% QoQ

Source: XBRL data from the MapLight Therapeutics, Inc. (MPLT) Q3 2026 10-Q on SEC EDGAR. USD.

MapLight Therapeutics, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no product sales
  • Operating margin not applicable, operating loss $55.3M vs $31.5M YoY
  • R&D expenses $44.2M vs $27.1M, driven by clinical trials and employee costs
  • Cash, equivalents and investments $463.4M; operating cash used $131.7M
  • Outlook: cash expected to fund operations through 2028, further funding required thereafter

Risk Factors

  • Newly triggered supply-chain risk: BIOSECURE Act enacted December 18, 2025 may affect a CDMO and restrict certain Chinese biotechnology suppliers
  • Most materially updated regulatory risk: OBBBA signed July 4, 2025 may reduce ACA coverage and Medicaid enrollment
  • Clinical risk: IRIS Phase 2 failed its primary endpoint in June 2026
  • Operational risk: ML-007C-MA relies on limited single-source manufacturing suppliers
  • Financial risk: $463.4 million cash, equivalents and investments expected to fund operations through 2028

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other MapLight Therapeutics, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.